Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18's biggest ever datapalooza
Analysts are having a field day comparing notes on a slew of data that emerged at ASH over the last few days. One standout seems to be a warm regard for much of the new data coming out on the wrangle for lead spot among BCMA bispecifics, with CAR-T slipping in comparison.
Jefferies’ Michael Yee brought in a KOL to his investor lunch in San Diego and came away with this observation:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.